Alexza Pharmaceuticals has hired Peter W. Schineller as its new Senior VP and Chief Commercial Officer, responsible for global commercialization of the company’s Adasuve Staccato inhaled loxapine. The FDA approved Adasuve for the treatment of agitation in patients with schizophrenia or bipolar I disorder in December 2012. In Europe, the product was approved in February 2013.
Alexza President and CEO Thomas King commented, “We are very pleased to welcome Peter to Alexza as a member of our management team. He brings a wealth of commercial experience in many settings and with many products. The approvals of Adasuve in the US and the EU now make Adasuve a global brand. Peter will lead our commercialization strategies for Adasuve as we focus on product launches later this year. Moreover, Peter’s diverse experience in introducing and promoting healthcare products is a great fit for contributing to Alexza and shaping our product pipeline opportunities.”
Schineller, who was most recently employed at Ventana Medical Systems as Senior VP and General Manager, added, “With the recent approval of Adasuve in the US and EU, this is an exciting time to join the talented team at Alexza. Alexza is putting in place a number of important launch preparatory activities, and we are focused on having the elements we believe will support a successful commercial launch of Adasuve in the US and in Europe.”
Read the Alexza press release.
